BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250819
DTEND;VALUE=DATE:20250822
DTSTAMP:20260515T044527
CREATED:20250509T085540Z
LAST-MODIFIED:20250509T085540Z
UID:41058-1755561600-1755820799@www.pharmajournalist.com
SUMMARY:9th IPF Summit
DESCRIPTION:This August\, the 9th IPF Summit returns as the industry’s must attend summit\, providing an essential platform for the entire community to gather and dissect the latest breakthroughs and setbacks\, to shape the future of pulmonary fibrosis drug development. \nBe one of the first to view the agenda here: https://ter.li/moky9n \nA Snapshot of What Awaits You in 2025: \n\nCase Study on the Path to Phase 3 Success: Hear directly from Boehringer Ingelheim’s Susanne Stowasser and Matthew Thomas as they unpack nerandomilast’s journey from discovery through to clinical success\nBrand-New From Setbacks to Solutions Seminar Afternoon: Analyze recent Phase 2 and 3 trial failures from with expert insights from Pfizer and former leaders at Galecto and Galapagos\nNavigating a Shifting Treatment Landscape: Explore how clinical benchmarks are changing and how new therapies must position themselves\, with input from Boehringer Ingelheim\, BMS\, and Insilico Medicine\nEnhancing Preclinical Confidence: Discover what a high-confidence translational package looks like in 2025\, featuring case studies from GSK\, Boehringer Ingelheim\, and others.\n\nIf ever there was a time to invest in this community and a conference\, it’s now. Join us to gain the full spectrum of insight needed to bring better IPF therapies to patients – faster. \nFind all the information needed here: https://ter.li/moky9n
URL:http://www.pharmajournalist.com/event/9th-ipf-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250819
DTEND;VALUE=DATE:20250822
DTSTAMP:20260515T044527
CREATED:20250425T132731Z
LAST-MODIFIED:20250425T132731Z
UID:40998-1755561600-1755820799@www.pharmajournalist.com
SUMMARY:3rd ADC Linker & Conjugation Summit
DESCRIPTION:As dual-payload and novel MoA payload ADCs continue to reshape the therapeutic landscape\, the 3rd ADC Linker & Conjugation Summit returns as the definitive forum for ADC chemists and bioconjugation specialists aiming to overcome persistent challenges in hydrophobicity\, aggregation\, and linker stability. \nThis three-day technical deep dive is your chance to: \n\nDiscover next-generation conjugation strategies and site-specific technologies\nTackle the unique challenges of dual-payload and novel payload ADCs\nBenchmark cutting-edge solutions for improved DAR control and linker stability\nAdvance ADC reproducibility and performance with chemistries beyond maleimide\n\nJoin 80+ industry experts\, including ADC chemists\, biotech innovators\, and service providers\, all focused on refining ADC design for enhanced PK profiles and safety. \nExplore the brand-new event guide and be part of the community driving the next wave of ADC innovation. https://ter.li/387nz1
URL:http://www.pharmajournalist.com/event/3rd-adc-linker-conjugation-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250805
DTEND;VALUE=DATE:20250808
DTSTAMP:20260515T044527
CREATED:20250328T115942Z
LAST-MODIFIED:20250404T112846Z
UID:40784-1754352000-1754611199@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences East
DESCRIPTION:Join us this August in Boston\, MA for the 9th LEAP HR: Life Sciences East. \nConnect with 200+ leadership professionals in biopharma dedicated to attracting\, retaining and developing critical talent to deliver their organizations mission. Engage with HR leaders who are also navigating a period of uncertainty amongst: regulation changes\, financial uncertainties\, supply chain disruptions\, and changing workforce dynamics. Leave with a ready-made support network of industry peers committed to building high-performing organizations. \nExplore 40+ case studies from leading drug development organizations on shifting to new systems of empowered teams\, accelerating the development of both current and future leaders\, and optimizing global team dynamics across diverse business layers. \nFind out more now: https://ter.li/v3bct4
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-east-2025/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T044527
CREATED:20250613T092615Z
LAST-MODIFIED:20250613T092615Z
UID:41264-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:5th Next Generation Gene Therapy Vectors Summit
DESCRIPTION:The 5th Next Generation Gene Therapy Vectors Summit \n \nRecent announcements from major pharmaceutical companies scaling back their AAV gene therapy pipelines have raised concerns across the field. However\, this is not the end. It is an opportunity to reset\, refocus\, and rise to the challenge. While issues such as liver toxicity\, pre-existing antibodies\, and high manufacturing costs remain significant\, so too does the unmatched potential of AAV vectors. From their ability to cross the blood-brain barrier to delivering single-stranded DNA for single-dose cures\, AAV continues to offer enormous therapeutic promise. \nThe 5th Next Generation Gene Therapy Vectors Summit returns to Boston this September to spotlight the scientists and leaders who are continuing to innovate in vector design. This meeting is designed for those who understand that strategic setbacks can often pave the way for transformative breakthroughs\, as we saw in the early development of ADCs. \nOver the course of 3 days\, the summit will bring together experts in vector engineering\, translational science\, and clinical development to explore how the field can advance in a more refined and resilient direction. Attendees will hear from thought leaders such as Daniel Cohen (Spark Therapeutics)\, Eric Kelsic (Dyno Therapeutics)\, Jorge Santiago-Ortiz (Apertura Gene Therapy)\, Lolita Petit (Coave Therapeutics)\, Ralf Schmid (Novartis)\, and Roxanne Croze (4D Molecular Therapeutics). \nThe program will explore the latest innovations in capsid engineering\, novel strategies to overcome immune responses\, scalable systemic delivery technologies\, and key clinical insights that can shape future development pipelines. \nWhether your focus is vector optimization\, CMC\, or clinical translation\, this summit provides a valuable opportunity to connect with the experts and technologies leading the next phase of gene therapy innovation. Join the community in Boston this July and help shape a safer\, smarter\, and more successful future for AAV. \nFind Out More Here: https://ter.li/8qkdsh
URL:http://www.pharmajournalist.com/event/5th-next-generation-gene-therapy-vectors-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T044527
CREATED:20250520T095035Z
LAST-MODIFIED:20250520T095035Z
UID:41125-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:5th Fc-Mediated Function Summit
DESCRIPTION:The landscape of Fc-mediated therapies is undergoing a radical transformation\, driven by precise Fc-receptor targeting and antibody domain modification to unlock new levels of efficacy and safety for unprecedented therapeutic potential in oncology and autoimmune disease treatment. The 5th Fc-Mediated Function Summit is the essential destination for experts driving innovation in Fc-receptor targeting and antibody domain modification. \nThis year\, we’re evaluating the cutting-edge of Fc biology and engineering\, diving deep into the game-changing potential of novel Fc modifications\, bispecific formats\, and targeted effector functions to revolutionize the treatment of cancer\, autoimmune diseases\, and beyond. Hear from the titans of the pharmaceutical industry\, including AbbVie\, Novartis\, and UCB as well as innovative biotechs including Seismic Therapeutics\, Paradigm Immunotherapies\, and many more – as they share their groundbreaking research and strategies for developing more effective\, safer\, and long-lasting fc-mediated solutions. The therapeutic potential of Fc-mediated functions is surging following last year’s wave in FDA approvals from BeiGene’s Tevimbra to Genetech’s approval of Piasky\, and the pressure is on to continue this success and develop best-in-class treatments. \nWhy Attend? \n\nNavigate the latest insights into Fc receptor interactions and unlock the potential of precisely engineered antibodies for targeted efficacy and enhanced safety profiles\nConfront the challenges in therapeutic antibody development head-on by exploring novel Fc engineering strategies and optimizing treatment outcomes across diverse disease indications\nHear from 22+ industry luminaries and thought leaders\, including Sally Ward and Richard Blumberg\, and a multitude of companies who are pushing the boundaries of antibody engineering and Fc-mediated therapeutics\, including Argenx\, UCB\, and Boehringer Ingelheim\n\nDon’t miss this pivotal opportunity to network with 50+ leading scientists and drug development experts in the field of Fc-Mediated Function\, forge crucial collaborations\, and be part of the solution. The future of antibody therapeutics is being written now – be a part of it! \nRegister now.
URL:http://www.pharmajournalist.com/event/5th-fc-mediated-function-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T044527
CREATED:20250516T043336Z
LAST-MODIFIED:20250516T043336Z
UID:41089-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:Operationalize: Expanded Access Programs Summit West
DESCRIPTION:The Operationalize: Expanded Access Programs Summit West is coming to San Francisco! (July 29-31). \nFollowing the successful Boston and London meetings\, the Operationalize Expanded Access Programs Summit West is uniting stakeholders executing Early Access\, Expanded Access and Post-Trial Access Programs to share expertise in successfully bridging the gap between innovative clinical research and patients in need. \nThis Summit is the only West Coast forum connecting Expanded Access teams with industry peers to share case studies in overcoming operational and regulatory challenges to streamline access to life-changing therapies! \nFind out more at our website: https://ter.li/9ft05e. \nJoin 60+ experts\, from Eli Lilly\, Gilead\, Ultragenyx\, Daiichi Sankyo and more for three jam-packed days in San Francisco this July. Get exclusive insights\, real-world case studies and cutting-edge strategies to supercharge your Expanded Access Programs.
URL:http://www.pharmajournalist.com/event/operationalize-expanded-access-programs-summit-west/
LOCATION:The Clift Royal Sonesta\, 495 Geary Street\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250729
DTEND;VALUE=DATE:20250801
DTSTAMP:20260515T044527
CREATED:20250321T130027Z
LAST-MODIFIED:20250321T130140Z
UID:40739-1753747200-1754006399@www.pharmajournalist.com
SUMMARY:4th Targeted Radiopharmaceuticals Summit US
DESCRIPTION:As demand for radiopharmaceuticals rises\, the industry is focused on strengthening isotope supply\, improving patient access\, and accelerating therapeutic development. \n \nJoin us at the 4th Targeted Radiopharmaceuticals Summit US in San Diego this July for the premier platform dedicated to radiopharmaceutical therapeutics and theranostics\, featuring: \n\n50+ Expert Speakers from leading biotech\, pharma\, and research institutions\, including Ratio Tx\, Abdera\, Alpha-9\nOncology\, Novartis\, AstraZeneca\, UCLA\, UCSF\, and more\n275+ Industry Attendees driving advancements from bench to bedside\n11+ Hours of Networking with top professionals\n3 Dedicated Tracks: Discovery & Preclinical\, Translational & Clinical\, and Clinical & Supply Chain\, curated to address key challenges\n\nOffering a tightly focused agenda dedicated to industry-specific topics\, this event is designed to advance approvals and commercialization. \nExplore critical areas such as isotope supply\, clinical development\, regulatory clarity\, novel molecule design\, investment and funding and much more. \nDon’t miss this essential event for anyone involved in the radiopharmaceuticals space! \nView the exclusive program here.
URL:http://www.pharmajournalist.com/event/4th-targeted-radiopharmaceuticals-summit-us/
LOCATION:The Hyatt Regency La Jolla\, 3777 La Jolla Village Drive\, San Diego\, CA\, 92122\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250722
DTEND;VALUE=DATE:20250724
DTSTAMP:20260515T044527
CREATED:20250430T133531Z
LAST-MODIFIED:20250430T133531Z
UID:41019-1753142400-1753315199@www.pharmajournalist.com
SUMMARY:13th Tumor Models Summit Boston
DESCRIPTION:This July\, the 13th Tumor Models Summit Boston returns\, uniting 180+ preclinical and translational experts from biopharma and solution providers. \nThis year’s dual-track program will empower you and your team to implement reproducible\, predictive oncology models\, and bridge the translational gap in a time- and cost-effective manner. \nExpect to gain exclusive insights into: \n\nThe latest applications of tumoroids\, patient-derived in vivo\, ex vivo\, in silico and genetically engineered models\nOptimized protocols to humanize complex in vitro and mouse models\nApplying reverse translation and clinical learnings to better stratify patients\, focus treatment regimens\, and improve patient outcomes\nPractical applications of digital pathology and spatial biology to advance your model selection strategy\n\nEvent information and quick links: \n\nLocation: Westin Boston Seaport District\, Boston\, MA\nDates: July 22-23\, 2025\nEvent Guide: https://ter.li/dz9th5\nRegistration (FREE* for biopharma!): https://ter.li/d6bden\n\n*Subject to terms and conditions\, visit the website to learn more: https://ter.li/d6bden
URL:http://www.pharmajournalist.com/event/13th-tumor-models-summit-boston/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250721
DTEND;VALUE=DATE:20250724
DTSTAMP:20260515T044527
CREATED:20250304T115052Z
LAST-MODIFIED:20250304T115052Z
UID:40636-1753056000-1753315199@www.pharmajournalist.com
SUMMARY:5th mRNA-Based Therapeutics Summit
DESCRIPTION:The mRNA field is on the cusp of revolutionary change\, with cancer vaccines\, in vivo cell engineering and gene editing technologies unleashing the next advancements of therapeutic candidates and developmental progress towards clinical and commercial approval. \nTo shine light on emerging areas and the latest progress\, the 5th mRNA-Based Therapeutics Summit returns to Boston as the world’s largest\, end-to-end mRNA conference\, gathering 350+ global stakeholders\, sharing exclusive scientific and strategic insights from the biggest and newest players in the mRNA\, Circular RNA & SaRNA fields including Moderna\, Pfizer\, BioNTech\, Grann Pharmaceuticals\, Celestial Therapeutics. \nDiscover the realms of new infectious disease platforms\, combating oncological targets and cell therapies across 4 dedicated tracks of content in Discovery\, Pre-Clinical Development\, Clinical Development and Manufacturing & CMC\, as your one-stop-shop scientific content and partnering forum to aid the progress of pipelines in 2025 towards the clinic and ultimately patients in need. \nDownload the event guide for full details: https://ter.li/esarrv
URL:http://www.pharmajournalist.com/event/5th-mrna-based-therapeutics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250715
DTEND;VALUE=DATE:20250718
DTSTAMP:20260515T044527
CREATED:20250409T111422Z
LAST-MODIFIED:20250411T115959Z
UID:40893-1752537600-1752796799@www.pharmajournalist.com
SUMMARY:5th Inner Ear Disorders Therapeutics Summit
DESCRIPTION:Building on recent breakthroughs in gene therapy\, 2025 is poised for major advancements in cell transplants\, gamma secretase inhibitors\, anti-inflammatory programs\, and more to address the growing unmet need for more transformative hearing loss treatments. \n \nWith an aging population and an urgent need to restore a greater spectrum of hearing abilities beyond the scope of current device-based interventions\, there has never been a more critical time for the field to unite and drive progress. \nCoined by industry as the only meeting of its kind\, uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical\, translational\, and clinical bottlenecks\, the 5th Inner Ear Disorders Therapeutics Summit returns as your definitive forum to benchmark learnings from past failures and ignite renewed optimism into the hearing loss therapeutic landscape. \nWith pioneering insights from Regeneron\, Biogen\, Acousia\, Rinri\, Ting Therapeutics\, Lineage Cell Therapeutics\, Gateway and more\, join 50+ of your peers to: \n\nAdvance translatable models to recapitulate complex human inner ear pathophysiology\nDeepen knowledge of molecular and genetic pathways underlying age-related\, noise-induced\, and congenital hearing loss to uncover druggable pathways\nEvaluate clinical progress in gene therapy for restored hearing and decipher the journey to success in Phase III populations\nOvercome translational challenges of bringing advanced therapies\, including small molecule and cell-based approaches\, to the clinic\nUncover opportunities for drug-device combinations to enable precise drug delivery and enhance the hearing preservation capabilities of cochlear implants\nHear large pharma and investor perspectives on what must be demonstrated to de-risk business opportunities within the hearing disorders space\n\nJoin this unparalleled forum of biotech innovators\, pharma stakeholders\, medical device manufacturers\, and leading academics in a collaborative atmosphere to advance otoprotection\, hearing restoration\, and gene therapy R&D and transform the treatment of hearing loss. \nFind out more in our brochure: https://ter.li/22rawz
URL:http://www.pharmajournalist.com/event/5th-inner-ear-disorders-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250714
DTEND;VALUE=DATE:20250717
DTSTAMP:20260515T044527
CREATED:20250214T115327Z
LAST-MODIFIED:20250214T115819Z
UID:40483-1752451200-1752710399@www.pharmajournalist.com
SUMMARY:3rd Obesity & Weight Loss Summit
DESCRIPTION:The 3rd Obesity & Weight Loss Summit has been announced and is set to ignite the field.  The summit will unite experts to harness novel targets and GLP combination therapies to improve efficacy\, tolerability\, and longer lasting clinical outcomes. \n \nJoin us at this unique\, industry-led summit to: \n\nDiscover groundbreaking combination therapies and novel targets to minimize and manage side effects to improve patient tolerability with Boehringer Ingelheim and Altimmune\nExplore innovative approaches for preserving muscle mass whilst still achieving significant weight loss to prevent sarcopenia with Regeneron and iBio\nInvestigate cutting-edge advancements in drug delivery technologies\, including long-acting formulations and novel administration routes for simpler patient use with Biolexis and Syntis Bio\nLearn strategies to drive long-term weight management success by personalizing treatment for more prolonged patient continuation and satisfaction with Prive Bio and Fractyl Therapeutic\n\nHear from the titans of the pharmaceutical industry – Eli Lilly\, Novo Nordisk\, AstraZeneca\, Altimmune\, High Tide Therapeutics\, RenBio\, and many more – as they share their groundbreaking research and strategies for developing more effective\, tolerable\, and long-lasting weight management solutions. \nObesity rates are increasing\, and the pressure is on for real change. Don’t miss this pivotal opportunity to network with 70+ obesity scientists and drug development experts forge collaborations\, and be part of the solution. The future of weight loss treatment is being written now – be there! \nFor more information\, view the full Event Guide here: https://ter.li/rish42
URL:http://www.pharmajournalist.com/event/3rd-obesity-weight-loss-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250708
DTEND;VALUE=DATE:20250711
DTSTAMP:20260515T044527
CREATED:20250409T113017Z
LAST-MODIFIED:20250409T113017Z
UID:40910-1751932800-1752191999@www.pharmajournalist.com
SUMMARY:3rd ADC Toxicity Summit
DESCRIPTION:“Toxicity is the killer of ADCs” and remains the primary challenge limiting ADC success in the clinic. From unpredictable off-target effects to non-translating toxicity profiles and dose limiting toxicities\, the industry must address key hurdles in preclinical models\, patient selection\, ADC design\, and cross-disciplinary communication to accelerate the next wave of safer\, more effective ADCs. \nThe 3rd ADC Toxicity Summit is the only industry-led event bringing together toxicology\, pharmacology\, translational science\, and clinical development experts to accelerate bench-to-bedside-to-bench innovation by preventing\, predicting\, and mitigating toxicities to enhance ADC safety and clinical translation. \nTo know more visit: https://ter.li/57358v
URL:http://www.pharmajournalist.com/event/3rd-adc-toxicity-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250708
DTEND;VALUE=DATE:20250711
DTSTAMP:20260515T044527
CREATED:20250404T111858Z
LAST-MODIFIED:20250404T111858Z
UID:40858-1751932800-1752191999@www.pharmajournalist.com
SUMMARY:ESG in Life Sciences Summit West
DESCRIPTION:The ESG in Life Sciences Summit West – Mastering ESG Compliance & Strategic Sustainability in Life Sciences in 2025. \nAs ESG becomes a key differentiator for securing business and investment\, life sciences companies are ramping up sustainability efforts – expanding teams\, funding new initiatives\, and integrating ESG into corporate strategy. Yet\, with shifting global reporting requirements\, the new administration’s stance on sustainability\, and the impact of CSRD on U.S. operations\, many companies are struggling to find the golden ticket on how they can future-proof ESG initiatives and ensure accuracy in reporting? \nAt the same time\, mounting pressure from investors\, consumers\, and employees to accelerate environmental and social initiatives is leaving many searching for the most effective strategies to navigate the evolving ESG landscape. \nFollowing the success of our Boston and European editions\, the ESG in Life Sciences Summit West is bringing together senior leaders in ESG\, Sustainability\, Compliance\, Procurement\, Supply Chain\, and Finance from across the West Coast to: \n\nDecode the impact of evolving U.S. and EU regulations on ESG reporting\nDrive sustainable supply chain transformation\nOptimize ESG strategies for business growth\n\nJoin us in driving the future of Life Sciences sustainability – turning ambition into action\, compliance into opportunity\, and responsibility into lasting impact for people and the planet! Find out more here: https://ter.li/oggmq8
URL:http://www.pharmajournalist.com/event/esg-in-life-sciences-summit-west/
LOCATION:The Clift Royal Sonesta San Francisco\, 495 Geary St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250626
DTEND;VALUE=DATE:20250628
DTSTAMP:20260515T044527
CREATED:20250404T112624Z
LAST-MODIFIED:20250404T112624Z
UID:40863-1750896000-1751068799@www.pharmajournalist.com
SUMMARY:4th Liquid Biopsy for Precision Oncology East Coast
DESCRIPTION:The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda\, sharpened focus\, and a renewed mission: to accelerate access to more sensitive\, less invasive testing by addressing the most pressing challenges across the entire patient care continuum. \nThis year\, we’ve updated the Summit’s name and expanded its scope. What began with a focus on early detection and recurrence monitoring has grown to reflect the full breadth of innovation across the liquid biopsy space – from MRD and treatment response to emerging applications in rare diseases\, novel analytes\, and beyond. \nBringing together leaders in Biomarker Development\, Translational Research\, Diagnostics\, Clinical Development\, Pathology\, and beyond\, this is the go-to East Coast forum for diving deep into the barriers slowing the adoption of liquid biopsy technologies. \nTake home actionable insights to ensure you’re maximizing the value of liquid biopsies in your therapeutic development strategies. Shape the future of precision oncology and be part of the conversations that will drive meaningful change for patients worldwide. \nWhat’s more\, this event is completely *FREE for drug developers and researchers for the entire 2 day conference\, so claim your pass here (it only takes 2 minutes): https://ter.li/mr0yvh \nIf you need to explore the full event guide in more detail\, feel free to download the brochure here: https://ter.li/mxugsc \nT&Cs are available on the website.
URL:http://www.pharmajournalist.com/event/4th-liquid-biopsy-for-precision-oncology-east-coast/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250625
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T044527
CREATED:20250401T093821Z
LAST-MODIFIED:20250401T093821Z
UID:40798-1750809600-1750982399@www.pharmajournalist.com
SUMMARY:5th Annual Induced Proximity-Based Drug Discovery Summit
DESCRIPTION:Coming to San Diego\, CA for the first time\, the 5th Induced Proximity-Based Drug Discovery Summit returns as your intimate learning and networking setting to cover the depth and breadth of proximity-based drugs from stabilization\, phosphorylation and methylation to novel lysosome-based degradation to finally drug the undruggable. \nEnabling leaders in biopharma and academia to identify novel MoAs\, leverage advanced technologies to find targets more efficiently\, and optimize chemical structures for more effective therapeutic agents for a wide range of disease areas. Alongside key strategic updates on DUBTACs\, RIPTACs\, tPRIMEs\, RiboTACs and more\, it provides granular technical and scientific insights to overcome challenges in accessing diverse chemical matter and designing selective\, potent small molecules of tomorrow. \nJoin 70+ experts in drug discovery\, medicinal chemistry\, chemical biology and structural biology from leading companies such as Genentech\, Halda Therapeutics and Stablix and gain access to genuinely innovative research from breakthrough companies and academic labs pioneering the next generation of induced proximity-based drugs beyond the ubiquitin proteasome system \nDownload the event guide for full details: https://ter.li/blor1c
URL:http://www.pharmajournalist.com/event/5th-annual-induced-proximity-based-drug-discovery-summit/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T044527
CREATED:20250409T112357Z
LAST-MODIFIED:20250409T112504Z
UID:40904-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:8th International Neoantigen Summit
DESCRIPTION:2024 saw a wealth of clinical progression with Nouscom\, CureVac\, Transgene and other pioneering companies paving the way for neoantigen based vaccines and therapies to become tolerable\, durable medicines to effectively treat cancer.\nReady to unite the global neoantigen community\, the 8th International Neoantigen Summit 2025 returns to address key challenges in the discovery\, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients. \nJoin neoantigen leaders from the likes of AstraZeneca\, Geneos Therapeutics\, Evaxion Biotech and many more at this end-to-end meeting\, focusing on the development of durable\, neoantigen cancer vaccines and cell therapies. With the potential to deliver safe\, efficacious personalized or off-the-shelf therapeutic options to patients\, this is your chance to collaborate and accelerate the translation of neoantigen-based therapies from discovery to clinical success. \nTo know more visit: https://ter.li/zdfjes
URL:http://www.pharmajournalist.com/event/8th-international-neoantigen-summit/
LOCATION:Steigenberger Airport Hotel Amsterdam\, Stationsplein Zuid-West 951\, 1117 CE Schiphol\, Netherlands\, 1117 CE\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T044527
CREATED:20250304T114230Z
LAST-MODIFIED:20250304T114358Z
UID:40629-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:5th Medical Device Software Development Summit
DESCRIPTION:The 5th Medical Device Software Development Summit is your must-attend opportunity to gain actionable strategies\, real-world case studies\, and expert insights to confidently develop\, secure\, and regulate cutting-edge medical device software – without compromise. \nDedicated to navigating the complexities of US and global regulations\, addressing cybersecurity vulnerabilities\, and managing legacy device updates\, this summit unites 120+ industry leaders – from medical device giants to innovative start-ups – to explore actionable strategies\, share best practices\, and collaborate on solutions for ensuring the continuous compliance and security of cutting-edge software in a rapidly evolving market. \nWhat Will you Gain: \n\nStay Ahead of Regulatory Changes: Gain insights from Biogen\, Werfen\, and Olympus on the latest FDA\, EU MDR\, and global compliance updates\, ensuring your products meet evolving standards.\nSecure & Accelerate Your Software: Learn how Medtronic\, RETINA-AI\, and Abbott are addressing cybersecurity risks\, enhancing software validation\, and leveraging AI-powered innovation to streamline development processes.\nUnlock AI for Safer\, Faster Development: Discover how HeartSciences\, Kheiron\, and Globe Biomedical are utilizing AI to expedite software testing\, improve validation\, and bolster cybersecurity\, leading to safer and more efficient medical device development.\n\n\nDon’t miss this summit – join us in Boston this June to stay ahead\, gain crucial insights\, benchmark and fuse knowledge from software\, QA\, RA and product teams to align innovation in software with evolving processes\, cybersecurity\, and global regulatory frameworks in new and legacy devices. \nView the full Event Guide here: https://ter.li/cziksw
URL:http://www.pharmajournalist.com/event/5th-medical-device-software-development-summit/
LOCATION:The Royal Sonesta Boston\, 40 Edwin H Land Blvd\, Cambridge\, MA\, 02142\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250624
DTEND;VALUE=DATE:20250627
DTSTAMP:20260515T044527
CREATED:20250225T182337Z
LAST-MODIFIED:20250228T133908Z
UID:40588-1750723200-1750982399@www.pharmajournalist.com
SUMMARY:CPHI & PMEC China 2025
DESCRIPTION:CPHI & PMEC China is Asia’s premier pharmaceutical event for sourcing\, networking\, learning and innovation with over 20 years’ experience of bringing together Chinese and global pharma professionals. \n \nCPHI & PMEC China 2025 will cover more than 230\,000 square meters of exhibition area\, attract over 90\,000 global attendees and 3\,500 exhibitors\, and hold more than 100 conferences during the exhibition. \nCPHI & PMEC China 2025 showcases a wide range of pharmaceutical products and services\, including: active pharmaceutical ingredients\, Intermediates & fine chemicals\, excipients\, finished dosage formulation\, biopharmaceuticals\, natural extracts\, CMO & CRO\, machinery & equipment\, packaging & drug delivery\, laboratory equipment\, cleanroom & pollution control etc. \nClick here to register now.
URL:http://www.pharmajournalist.com/event/cphi-pmec-china-2025/
LOCATION:Shanghai New International Expo Centre\, Shanghai\, China
ORGANIZER;CN="Shanghai Sinoexpo Informa Markets International Exhibition Co.%2C Ltd.":MAILTO:CPHImarketing@imsinioexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250623
DTEND;VALUE=DATE:20250626
DTSTAMP:20260515T044527
CREATED:20250327T135543Z
LAST-MODIFIED:20250328T115442Z
UID:40760-1750636800-1750895999@www.pharmajournalist.com
SUMMARY:10th Annual Microbiome Movement Summit
DESCRIPTION:Returning for its 10th anniversary\, the Microbiome Movement Summit remains the premier global gathering for microbiome drug developers\, uniting experts across discovery\, preclinical\, translational\, regulatory\, and commercial sectors to drive innovation in the microbiome space. \nConnect with over 140+ experts from diverse fields within microbiome R&D\, including representatives from Pulmobiotics\, Seres Therapeutics\, BiomeBank\, and PharmaBiome. Engage in dynamic discussions\, forge valuable partnerships\, and gain actionable insights that will drive your microbiome research and development forward. This summit is your chance to be at the forefront of microbiome innovation and to collaborate with the brightest minds in the industry. \nWhat’s New for 2025? \n– Hear Brand New Insights from Industry Trailblazers: Gain key updates from leaders at Ferring Pharmaceuticals\, Siolta Therapeutics\, MaaT Pharma\, and Corundum Systems Biology as they discuss clinical advancements and commercial strategies shaping the future of microbiome therapeutics. \n– 18 New Organizations Taking the Stage: Discover the latest contributions from emerging companies such as Azitra\, Kanvas Bio\, Alveolus Bio\, Microviable Therapeutics\, Unilever\, Mikrobiomik\, Jona\, Nestle Health Science\, and more\, with each presenting their innovative approaches and breakthroughs in microbiome research. \n– Unlock the Next Wave of Microbiome-Based Drug Development: Explore groundbreaking synthetic biology innovations\, AI-driven strain engineering\, and advanced bioinformatics tools that are accelerating the discovery and optimization of microbiome-based therapies. \n– Advance Clinical Translation & Regulatory Success: Learn how companies are overcoming challenges in CMC\, large-scale manufacturing\, and regulatory approval\, with insights on recent FDA approvals\, IND-enabling studies\, and global market access strategies. \nGet your copy of the latest brochure here: https://ter.li/cdfr4c
URL:http://www.pharmajournalist.com/event/10th-annual-microbiome-movement-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T044527
CREATED:20250305T141309Z
LAST-MODIFIED:20250305T142300Z
UID:40667-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:4th World ADC Asia Summit
DESCRIPTION:Linking the East to the West in the ADC World | 在ADC世界连接东西方 | ADC 세계에서 동서 연결하기ADCの世界で東西をつなぐ \nIn 2025\, Asia will continue leading ADC innovation\, with growth in dual-payload ADCs\, bispecific ADCs\, and novel linker-payload technologies. Staying informed through clinical updates\, connecting with new companies\, and building collaborations will be key to seizing emerging opportunities. \nThe 4th World ADC Asia Summit (June 10-12\, 2025\, | Incheon\, South Korea)\, part of the globally recognized World ADC series\, serves as the premier platform for showcasing the latest advancements in R&D\, clinical validation\, and commercialization. \nThis industry-leading event unites Asia’s top innovators with global expertise to drive ADC success across the region. \nWhat’s New in 2025? \n Three dynamic tracks covering discovery\, preclinical\, clinical\, and CMC\nExclusive seminar days on ADC fundamentals & Bispecific ADCs – Whether you’re just starting out or a seasoned expert\, the program offers something for professionals at every level\n Unparalleled networking with leading experts and organizations \nA Global Speaker Lineup \nWith 20+ new companies joining our esteemed panel from China\, Japan\, Korea\, Taiwan\, Singapore\, the US\, and Europe—featuring industry leaders such as AstraZeneca\, AbbVie\, HoneyBear Biosciences\, Chiome Bioscience\, and more—this is a must-attend event for anyone in the ADC field. \nLearn more here: https://ter.li/iimxna
URL:http://www.pharmajournalist.com/event/4th-world-adc-asia-summit/
LOCATION:Grand Hyatt Incheon\, 208 Yeongjonghaeannam-ro 321beon-gil\, Jung-gu\, Incheon\, South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T044527
CREATED:20250409T111953Z
LAST-MODIFIED:20250409T111953Z
UID:40897-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:Vendor Management & Outsourcing for Clinical Trials Summit
DESCRIPTION:Vendor management processes are crucial for ensuring compliance\, quality\, and timely delivery at every stage\, serving as the backbone of successful clinical trials. Acknowledging the transformative impact\, the industry is prioritizing the optimization of these intricate processes\, making significant investments to enhance key functions\, improve performance\, and maintain a competitive edge. Despite this professionals managing ancillary lab vendors and CROs lack a dedicated forum to address their unique challenges\, until now… \nIntroducing the Vendor Management & Outsourcing for Clinical Trials Summit\, built with the industry to the needs of vendor management\, outsourcing and clinical operations professionals. \nTo know more visit: https://ter.li/d1jemt
URL:http://www.pharmajournalist.com/event/vendor-management-outsourcing-for-clinical-trials-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T044527
CREATED:20250206T124225Z
LAST-MODIFIED:20250220T125930Z
UID:40428-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:2nd Annual IMPACCT Real World Evidence Summit Europe
DESCRIPTION:This year’s IMPACCT Real World Evidence Europe conference is the only case-study led industry forum providing actionable insights into numerous challenges such as optimizing evidence generation plans in early stages\, enhancing collaboration between industry and public research to advance RWE\, consolidating cross-functional collaboration to improve effectiveness of RWE studies\, and exploring actionable study designs that empower patients to elevate RWE utility… \nAs regulators and payers increasingly elevate the importance of RWE in submission requirements and with an explosion of datasets opening up in parallel with advancing AI\, deep learning\, and large language models transforming big data analysis\, it has never been more critical to keep up with the matrix of country-specific regulatory nuances and industry case studies in optimizing integrated evidence plans\, bullet-proofing data quality\, and navigating vendor selection. \nThe 2nd IMPACCT Real World Evidence Summit Europe is the only industry meeting dedicated to uniting experts in RWE and Evidence Generation to consolidate\, innovate and apply RWE across the drug development lifecycle\, from external control arms to reimbursement. \nWith a tight focus on leveraging AI for both efficiency gains and big data analysis\, the latest on DARWIN and using RWE to support regulatory decision-making\, and creating a robust integrated evidence strategy\, join 60+ industry pioneers from AstraZeneca\, Pfizer\, Novartis\, Sanofi and more to collaboratively establish best practice and bridge the evidence gap between clinical research and practice\, ensuring resilience and success in a dynamic landscape as a successful business partner. \nJoin us\, our speakers\, attendees and sponsors to explore strategies\, learn efficient data deployment and automation\, learn best practices for sharing real-time data and insights cross-functionally\, inform your development processes\, address biases and study product life cycle management to bridge the gap from clinical trials to real-world evidence. \nWith over 50 industry pioneers we have the force to form a comprehensive evidence plan\, break free from silos\, and bridge the gap between clinical research and practice. Get in the room with Presidents\, VPs\, Directors\, Head\, Managers and Lead Scientists all on the same mission as you. \nThis is your one opportunity to liaise with like-minded\, driven and curious individuals about industry innovation. \nTo know more visit: https://ter.li/e8cs7v
URL:http://www.pharmajournalist.com/event/2nd-annual-impacct-real-world-evidence-summit-europe/
LOCATION:Steigenberger Airport Hotel\, Amsterdam\, Stationsplein Zuid-West 951\, Schiphol\, 1117 CE\, Netherlands
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T044527
CREATED:20250108T111946Z
LAST-MODIFIED:20250108T112021Z
UID:40293-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:7th Annual Allogeneic Cell Therapies Summit
DESCRIPTION:With the autoimmune wave breathing financial life back into the allogeneic space\, and a growing number of oncology pipelines entering the clinic\, the allogeneic community are eagerly anticipating what lies ahead! \nMaking now the ideal time to attend the 7th Annual Allogeneic Cell Therapies Summit (June 10-12 | Boston\, MA)\, your flagship forum uniting the top allogeneic developers including Atara Bio\, Adicet Bio\, Senti Bio\, Glycostem and more. \nWhat Will 2025 Offer? \n\nGround-breaking Clinical Readouts: Dive into the latest results from CAR-T therapies with Atara Bio and Adicet Bio.\nSolid Tumor Breakthroughs: Hear from Senti Bio\, NKILT Therapeutics\, and Synaptimmune on how allogeneic therapies are targeting the tumor microenvironment to unlock entirely new indications.\nManufacturing at Scale: Learn how Tevogen and Cell BioEngines are navigating the complexities of scalable\, high-quality manufacturing to make these therapies commercially viable.\nBeyond Oncology: Broaden your scope by discovering how Biosyngen and Adicet Bio are leveraging allogeneic platforms to address autoimmune disorders.\n\nAs regulatory frameworks evolve to accommodate these revolutionary therapies and investment creeps back into allogeneic development\, staying informed is no longer optional. Get involved today to be part of the conversations solving today’s challenges and shaping tomorrow’s breakthroughs. \nFind out more: https://ter.li/o21go2
URL:http://www.pharmajournalist.com/event/7th-annual-allogeneic-cell-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250609
DTEND;VALUE=DATE:20250612
DTSTAMP:20260515T044527
CREATED:20250304T113738Z
LAST-MODIFIED:20250304T113738Z
UID:40624-1749427200-1749686399@www.pharmajournalist.com
SUMMARY:Innovation in Psychosis Therapeutics Summit
DESCRIPTION:The Innovation in Psychosis Therapeutics Summit is the premier industry forum dedicated to advancing next-generation approaches for psychosis treatment. As 2025 marks a pivotal year for psychosis drug development—with a surge in clinical advancements and key collaborations gaining momentum—this inaugural event unites the brightest minds in biotech and pharma to overcome critical challenges in drug discovery and development. \n \nDesigned specifically for R&D leaders\, this summit is uniquely positioned to tackle the biggest hurdles in the field\, including translational validity\, patient heterogeneity\, placebo effect\, and trial scalability. By bringing together 60+ key stakeholders from discovery\, preclinical\, translational\, and clinical development\, this meeting provides a platform to collaborate\, exchange insights\, and shape the future of psychosis treatment. \nWith the growing urgency to address the significant unmet need in psychosis and the limitations of current atypical antipsychotics\, the time is now to drive innovation forward. Join the conversation as industry pioneers build on Cobenfy’s breakthrough success and explore cutting-edge strategies to develop more effective\, better-tolerated therapeutics across the psychosis spectrum. \nDon’t miss this brand-new opportunity to connect with thought leaders\, gain critical insights\, and be at the forefront of transforming psychosis R&D. \nTo know more visit: https://ter.li/9yj2vx
URL:http://www.pharmajournalist.com/event/innovation-in-psychosis-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250603
DTEND;VALUE=DATE:20250606
DTSTAMP:20260515T044527
CREATED:20250228T121911Z
LAST-MODIFIED:20250228T121911Z
UID:40598-1748908800-1749167999@www.pharmajournalist.com
SUMMARY:2nd Structure-Based Drug Design Summit
DESCRIPTION:With tightening budgets and increasing pressure to de-risk R&D\, pharma and biotech are shifting their focus toward smarter\, more efficient drug design. Companies are investing more in enabling technologies—from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM\, NMR\, and X-ray crystallography—to improve rational drug design and enhance decision-making early in discovery. \nWhile AI-powered structure prediction is transforming the landscape—recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2— its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery. \nCryo-EM continues to push the limits of resolution for complex targets and Cryo-ET is emerging as a potential game-changer for biopharma – the future of structure-based drug design is here. \nThe 2nd Structure-Based Drug Design Summit is the only industry-dedicated meeting bringing together the latest advancements in integrative structural biology and computational tools to accelerate early drug discovery. Across three days of expert-led discussions and case studies\, you’ll gain insights into how leading scientists are leveraging Cryo-EM\, NMR\, X-ray crystallography\, and AI to solve high-value targets and drive rational drug design across small molecules\, peptides\, biologics\, and vaccines. \nWith coverage of design of TPDs\, molecular glues\, vaccines\, antibodies\, and mRNA\, GPCRs and membrane protein targeting therapeutics plus much more! \nThe field is evolving—don’t get left behind. Expand your network and join 80+ structural biologists\, medicinal chemists\, protein engineers\, and computational chemists in Boston this June and be part of the next wave of structure-based drug design innovation.
URL:http://www.pharmajournalist.com/event/2nd-structure-based-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T044527
CREATED:20250219T115152Z
LAST-MODIFIED:20250219T115152Z
UID:40525-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:3rd Gene Therapy Potency Assay Summit
DESCRIPTION:Accelerating the Route to Commercialization with Robust Potency Assay Development \nFollowing a challenging year in the gene therapy field\, the 3rd Gene Therapy Potency Assay Summit returns at a crucial time when drug developers increasingly recognize that a robust potency assay is fundamental to both clinical success and commercial viability. As regulatory expectations continue to evolve\, it has never been more important to develop assays that are accurate\, reproducible\, and aligned with regulatory standards. \nWhile many industry meetings touch on potency in a broad or non-technical manner\, this summit stands apart as the only event fully dedicated to the complexities of potency assay development. With an emphasis on deep technical discussions\, attendees will gain unparalleled insights into phase-appropriate assay development\, methodology advancements\, reducing lot-to-lot variability\, and meeting evolving regulatory expectations. By bringing together a specialized community of Analytical Development\, Quality Control\, and Regulatory experts\, this meeting offers a unique platform to discuss challenges\, share strategies\, and explore innovative solutions. \nOne of the key highlights of this year’s agenda is the session “Navigating Regulatory Requirements for Gene Therapy Potency Assays”\, presented by Melody Dai\, Vice President\, Head of Regulatory Affairs & CMC at Novasenta. This session\, taking place at 9:00 AM on Day 1\, will provide an in-depth exploration of regulatory strategies for potency assays\, covering both early and ongoing regulatory engagement. Attendees will learn how to build effective relationships with regulatory agencies\, navigate evolving requirements\, and prepare for critical regulatory meetings and submissions. By leveraging insights from experts with hands-on experience in clinical-stage gene therapy products\, this session will offer practical guidance that extends beyond theoretical discussions. \nWith a carefully curated agenda and contributions from industry leaders\, the 3rd Gene Therapy Potency Assay Summit provides an essential opportunity to advance potency assay strategies\, enhance regulatory preparedness\, and accelerate the path to commercialization. Whether you are refining your assay methodologies\, tackling regulatory complexities\, or preparing for the next phase of development\, this event will equip you with the expertise and connections needed to drive success in gene therapy. \nFind Out More Now!
URL:http://www.pharmajournalist.com/event/3rd-gene-therapy-potency-assay-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T044527
CREATED:20250217T143826Z
LAST-MODIFIED:20250217T143826Z
UID:40519-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:4th Circular & Self-Amplifying RNA Therapeutics Summit
DESCRIPTION:Join the 4th Circular & Self-Amplifying RNA Therapeutics Summit! \nUnleashing the Next Generation of RNAs for Widespread Therapeutic Applications \nWith CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine\, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability\, durability\, longevity and efficacy for treating a wide array of diseases. \nThis May\, the 4th Circular & Self-Amplifying RNA Therapeutics Summit (previously known as ‘Next Generation RNA Therapeutics Summit) is landing back in Boston\, as the unique opportunity to unite with leading stakeholders in the next generation RNA field\, including the likes of Sail Biomedicines\, Merck\, Novo Nordisk\, Replicate Bioscience and more. This is your one-stop shop to hear the latest approaches and applications of circular and self-amplifying RNA therapeutics and vaccines and gain actionable insights for fast-tracking your RNA programs toward the clinic. \nJoin 80+ RNA experts navigating through challenges such as RNA design\, delivery\, purity\, and manufacturing to accelerate high-quality and scalable next-generation RNA therapeutics and vaccines towards approval and the patients in need. \nTo know more visit: https://ter.li/lemzh2
URL:http://www.pharmajournalist.com/event/4th-circular-self-amplifying-rna-therapeutics-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T044527
CREATED:20250416T103747Z
LAST-MODIFIED:20250416T103747Z
UID:40951-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Current limitations across pricing\, coverage\, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. \nReturning for its 2nd edition\, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape. \nIndustry-led discussions will center on innovative payment models being developed and applied\, new stop-loss and reinsurance programs\, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes\, including the Access Model\, Medicaid Drug Rebate Program Final Rule\, and proposed increases to inpatient CAR-T reimbursement rates. \nJoin leading biopharma\, government agencies\, commercial payers\, academics\, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies\, enhance your payer coverage and improve patient access. \nTo know more visit: https://ter.li/0g5eq9
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T044527
CREATED:20250307T113641Z
LAST-MODIFIED:20250307T113641Z
UID:40683-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:3rd Retinal Imaging Biomarkers & Endpoints Summit
DESCRIPTION:The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors\, researchers\, clinical\, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging\, biomarkers\, and endpoints for ophthalmic drug development. \nThis highly anticipated meeting will delve into the evolving landscape of retinal diseases\, offering in-depth discussions on innovative imaging techniques\, biomarker discovery\, and the critical role of endpoints in clinical trials. Attendees will have the opportunity to engage with top-tier scientists\, researchers\, and industry leaders who will be presenting cutting-edge research\, techniques\, and case studies\, providing you with hyper-relevant insights to accelerate your ophthalmic development. \nTopics will cover a range of retinal conditions\, including dry and wet AMD\, GA\, GR\, and DME\, focusing on the identification and validation of biomarkers that are vital for diagnosis\, prognosis\, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval. \nAttendees will benefit from interactive workshops\, panel discussions\, and case studies\, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus\, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room\, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes. \nAnd with sessions being delivered by Alexion\, Opus Genetics\, Inflammx\, Bausch + Lomb\, REGENXBIO\, and many more you won’t want to miss this! \nWhether you’re a researcher\, drug developer\, clinician or solution provider\, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases. \nJoin us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health… \nView the event guide for more information: https://ter.li/hcmzr0 \nSecure your pass: https://ter.li/tq8jmz
URL:http://www.pharmajournalist.com/event/3rd-retinal-imaging-biomarkers-endpoints-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250520
DTEND;VALUE=DATE:20250523
DTSTAMP:20260515T044527
CREATED:20250422T121846Z
LAST-MODIFIED:20250422T122446Z
UID:40956-1747699200-1747958399@www.pharmajournalist.com
SUMMARY:6th Gene Therapy Analytical Development Summit Europe
DESCRIPTION:The 6th Gene Therapy Analytical Development Summit Europe is the leading platform for advancing gene therapy analytics\, from IND/IMPD filings to clinical trials and regulatory approvals. As the field moves toward late-stage development\, gain industry-focused insights tailored for Europe. \nJoin 24+ experts to tackle characterisation\, stability\, contamination risks\, and comparability across vectors and diseases. Network with biotech\, pharma\, MHRA\, and British Pharmacopoeia to share solutions and shape the future of gene therapy. \nDon’t miss the chance to explore analytical precision\, QC strategy\, and the delivery of safe\, effective therapies! \nTo know more visit: https://ter.li/w8deua
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-analytical-development-summit-europe/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR